KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report)'s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $8.87 and traded as high as $8.93. KalVista Pharmaceuticals shares last traded at $8.77, with a volume of 212,998 shares traded.
Analysts Set New Price Targets
Several research firms recently weighed in on KALV. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. TD Cowen initiated coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Bank of America began coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $22.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $25.00.
Check Out Our Latest Research Report on KalVista Pharmaceuticals
KalVista Pharmaceuticals Trading Up 2.8 %
The company's 50 day simple moving average is $8.87 and its 200-day simple moving average is $10.96. The firm has a market cap of $445.62 million, a P/E ratio of -2.49 and a beta of 0.86.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.
Insider Activity
In related news, CEO Benjamin L. Palleiko sold 14,400 shares of the business's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the transaction, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. The trade was a 5.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul K. Audhya sold 8,077 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock valued at $304,086 in the last quarter. 10.50% of the stock is currently owned by insiders.
Institutional Investors Weigh In On KalVista Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after buying an additional 2,043 shares during the period. SG Americas Securities LLC increased its stake in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after buying an additional 1,319 shares during the period. Hennion & Walsh Asset Management Inc. bought a new stake in KalVista Pharmaceuticals during the 4th quarter valued at about $634,000. JPMorgan Chase & Co. boosted its holdings in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after purchasing an additional 1,670 shares during the period. Finally, Barclays PLC increased its position in KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock valued at $778,000 after purchasing an additional 54,257 shares during the period.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Recommended Stories
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
